Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

January 5, 2024

https://www.globenewswire.com/news-release/2024/01/05/2804554/0/en/Liquidia-Provides-Update-on-Clinical-Pipeline-Targeting-PAH-and-PH-ILD.html

MORRISVILLE, N.C., Jan. 05, 2024 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ:LQDA) (Liquidia or the Company) provided an update today on the clinical progress of its pipeline programs to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) with its investigational drugs, YUTREPIA™ (treprostinil) inhalation powder and L606, a sustained-release inhaled formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer.

Read more at globenewswire.com

Related news for (LQDA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.